Part 1 of a two-part Deep GUNA Research series on cytokine biology, for practitioners.
This article is written for a practitioner audience and draws directly on GUNA's own published clinical reference material on cytokines. It is educational in nature, summarising cytokine immunology as background to GUNA's low-dose cytokine product range, and does not replace clinical judgement or personalised medical advice.
Cytokines sit at the centre of the GUNA Method's PNEI Rebalance phase, covered in our GUNA Method Therapeutic Triangle article. This article and the one that follows it work through the underlying cytokine immunology in detail — what cytokines are, how the immune reaction is controlled, and a full practitioner reference to the individual interleukins, interferons and related molecules GUNA offers as low-dose remedies.
Cell Communication: The Basis of Life
For the smooth operation of all physiological processes in the body, the roughly 60 trillion cells that make it up need to be able to communicate well. This communication happens via two classes of chemical substance: cytokines, and cell surface molecules. Communication can be direct — via an adhesion molecule, requiring cell-to-cell contact — or indirect, via a cytokine binding to a receptor at a distance.
The immune reaction itself is made up of a series of defined, controlled, and exactly progressing, inter-reactive steps. Cell activation, at each step, produces one or more cytokines and/or a specific membrane receptor pattern.
Controlling the Immune Reaction: Th1 and Th2
The immune reaction is controlled by immune cells via the release of pro-inflammatory and anti-inflammatory cytokines, conventionally grouped as follows:
- Th1 (pro-inflammatory / activating) cytokines: TNF, IL-1β, IL-2, IL-6, IFN-α, IFN-γ, and TGF.
- Th2 (anti-inflammatory / suppressing) cytokines: IL-4 and IL-10.
Pro-inflammatory cytokines drive up-regulation of the inflammatory response (IL-1, IL-2, IL-6, TNF-α, IFN-α, IFN-β), stimulate further pro-inflammatory cytokine production (IL-12), up-regulate acute phase reactants (IL-1, IL-6, IL-11, TNF-α, IFN-γ, TNF-β), and act as chemoattractants (IL-8). Anti-inflammatory cytokines work by inhibiting pro-inflammatory cytokine production — chiefly IL-4, IL-10 and IL-13.
One diagnostic concept GUNA's reference material draws attention to is the IL-2:IL-10 ratio as a two-point test of hyper- or hypo-mode immune function, without loss of clarity: a hyper-IL-10 / hypo-IL-2 pattern indicates an excess pro-inflammatory state, while a hypo-IL-10 / hyper-IL-2 pattern indicates excess inhibition of the immune system.
There's also an up- or down-regulation of adhesion molecules that accompanies the immune reaction — a change in the expression density and pattern of the various cell surface molecules involved.
Balance of Regulatory Systems
Cytokine activity is kept in balance, locally and systemically, by proteolytic serum activity — antiproteinases, hydrolase enzymes, cytokine receptors, and cytokine antibodies. Hydrolase enzymes, released locally, counteract excess cytokine production directly: they split and inactivate cytokines, and promote shedding of cytokine receptors from the cell surface.
Disturbances in the immune reaction occur when permanent immune-system stress shifts this balance beyond the system's capacity to compensate — the pattern seen in chronic, autoimmune and malignant disease. The typical shift is toward excess Th1 pro-inflammatory activity and decreased Th2 anti-inflammatory activity, producing unphysiological concentrations of immune complexes, antiproteinases, cytokines and adhesion molecules. Past a certain point, these effects stop being local and become systemic — a vicious spiral of inflammation and disease that leaves the body either under-defended against infection, or at increased risk of developing chronic, autoimmune or malignant disease.
Immune Deficiency: An Overview
Defensive performance can be insufficient or absent for several reasons: gene defects, damage to the immune system during tolerance development to a key toxin, or simple ageing. This favours deregulation of specific immune components, increased infection potential, persistence of antigens associated with chronic inflammation and faulty tissue regeneration, and — over time — increased potential for malignant disease.
The defensive posture can equally be excessive — from extreme antigen exposure, over-stimulation, or a lack of counter-regulation — or inhibited, from over-expression of immune complexes, cytokines or adhesion molecules. Both extremes either impede immune function directly or cause systemic side effects (HIV wasting syndrome is one example GUNA's material cites). Immune recognition of endogenous structures as foreign is the underlying cause of autoimmune disease; an excessive reaction to otherwise harmless substances — insufficient tolerance — is the underlying cause of allergy.
Types and Families of Cytokines
Immune cells secrete a large number of soluble, specialised mediators that guarantee viability, development, differentiation, proliferation and activity across the immune system. Cytokines are soluble glycoproteins that function as intercellular signalling molecules, and their reach extends well beyond immune cells — including cells of the nervous system. They're released in response to antigens, immune complexes, complement, enzymes, other cytokines, and direct cell-to-cell contact, and numerous cytokines are typically secreted concomitantly to initiate, regulate and terminate a given defensive step.
A change in target-cell function is always accompanied by a change in receptor density and pattern on the cell's surface membrane, particularly among the adhesion molecules. Unlike many hormone reactions, cytokine reactions — TNF, IFN, colony-stimulating factors, interleukins — are usually local, short-distance signals: released for a definite purpose, for a defined time, at a locally-limited site.
Two broad families are recognised:
- The TH-1 family — immune-stimulatory and pro-inflammatory: IL-1β, IL-2, IL-6, TNF.
- The TH-2 family — anti-inflammatory and immune-suppressive: IL-4, IL-10.
A deficiency in stimulatory or cytotoxic cytokines can directly limit the body's defensive capacity against both cancer cells and infection.
The Effect of Key Toxins
GUNA's material describes a specific cascade triggered by "key toxins" — the switch from Th2 anti-inflammatory to Th1 pro-inflammatory cytokine production. These Th1 cytokines initiate production of IL-2 and interferon-γ, which prompt phagocytes to produce reactive oxygen and nitrogen species; this in turn initiates TNF-α production, which changes cell function by interfering with mitochondrial oxidative phosphorylation — upsetting NADPH oxidase, the rate-controlling enzyme of the hexose-monophosphate shunt — and by stimulating nitric oxide synthase, increasing nitric oxide production.
A lack of suppressive cytokines removes the local counter-regulation that would otherwise stop this reaction. As GUNA's material puts it: "the cytokine network is a fine regulatory system. Both too much and too little of the individual cytokines has a negative effect." Unhindered cytokine formation leads to high concentrations — alone, or bound to antiproteinases — that are no longer confined locally but appear throughout the body as "vagabond structures," causing adverse effects at distant sites. GUNA identifies excessive cytokine formation, especially of IL-1 and TNF, as an immunopathogenetic mechanism in chronic inflammation, wasting syndrome, tumour-generating disease, chronic infection, septic shock, and a breakdown of the immune system (associated with IL-10).
General Activity of Cytokines
Cytokines play distinct, well-characterised roles depending on the phase of the immune response:
- In acute inflammation: TNF-α, IL-1, IL-6, IL-8, IL-11, alongside the chemokines G-CSF and GM-CSF.
- In chronic inflammation, mediating humoral responses: IL-4, IL-5, IL-6, IL-7, IL-13. Mediating cellular responses: IL-1, IL-2, IL-3, IL-4, IL-7, IL-9, IL-10, IL-12, interferon (IFN), TGF-β, TNF-α and TNF-β.
- In fever induction: IL-1, TNF-α and IL-6 initiate the PGE₂ series, altering the hypothalamic set point for body temperature.
- In ACTH production: IL-1 and IL-6 induce the pituitary-adrenal axis to produce ACTH, leading to cortisol release — which then inhibits further cytokine production, forming a negative feedback loop.
Tissue injury sets this whole cascade in motion: cytokine release following injury drives fever generation (via IL-1, TNF-α and IL-6 acting on the hypothalamic set point), ACTH-cortisol induction (via IL-1 and IL-6 acting on the pituitary-adrenal axis, with cortisol then inhibiting cytokine production), and hepatic acute phase protein synthesis — the liver's response to altered cytokine signalling.
The broader picture, working from antigens, phagocytosis, microorganisms, lectins, inflammatory agents and bacterial endotoxin acting on monocytes and lymphocytes: these stimuli produce IL-1 and TNF, and IL-1 acting on helper T cells produces IL-2, IL-4, IL-5 and IL-6. The downstream effects reach T and B cells (immune system activation), bone marrow (differentiation and proliferation of myeloid and haemopoietic cells), the liver (uptake of iron, zinc and amino acids; synthesis of glucose and acute-phase proteins), skeletal muscle, the brain (fever, anorexia, inhibition of lipoprotein lipase), and the endocrine organs and fat tissue (release of ACTH, steroids, insulin, glucagon, growth hormone and somatostatin).
Master Cytokine Reference Table
IL-1: The First Responder
Shop Interleukin 01 Beta (IL-1B) · Anti IL1
IL-1 comes mainly from macrophages and monocytes, induced by micro-organisms, microbial products, antigens, inflammatory agents, plant lectins, lymphokines, and certain chemicals. It activates the acute phase response — C-reactive protein, serum amyloid A, fibrinogen, complement, and alpha-1-antitrypsin — and induces fever, glucocorticoid hormone release, prostaglandin release, and collagenase-enzyme release. It activates vascular endothelial adhesion molecules (VCAM), stimulates IL-8 production (which in turn activates neutrophils), and elicits histamine release from mast cells at the inflammation site, increasing capillary permeability and causing vasodilatation.
IL-1 is also a potent mitogen for astroglial cells and induces astrocyte NGF synthesis. Separately, it interferes with the hypothalamic-hypophyseal-gonadal axis by decreasing plasma LH via inhibition of hypothalamic LHRH secretion and gene expression.
Major effects: fever, sleep, anorexia, inflammation, endothelial CD54 expression, tissue-factor release, lymphocyte activation, and production of IL-6, IL-8 and colony-stimulating factors.
IL-2: Immunologic Memory
Shop Interleukin 02 (IL2) · Guna Anti IL 2
IL-2 is generated by T lymphocytes following antigen or mitogen stimulation. It's a pro-inflammatory cytokine and a critical regulator of both cellular and humoral chronic inflammatory responses.
Host defence against bacteria typically works through phagocytosis and antibody formation; defence against viral, fungal and intracellular pathogens works through cytotoxic attack. Immunologic memory sits behind both: B lymphocytes are bone-marrow derived and become plasma cells secreting antigen-specific antibodies, while T lymphocytes are bone-marrow derived but thymus-matured — cytotoxic "killer" T cells kill infected or abnormal cells on contact, and "helper" T cells secrete cytokines. Once an antigen binds a T-cell receptor, the cell secretes both IL-2 and IL-2 receptors — the IL-2 receptor then functions as an on-off switch for the whole response, via two distinct receptor binding sites governing T-cell clonal proliferation, antigen specificity, and memory-cell formation.
IL-2 stimulates B-cell proliferation and antibody secretion, and killer T cells respond to it immediately — making it a first line of defence against intracellular pathogens. It may also influence lymphocyte maturation and differentiation in the thymus and bone marrow. Clinically, IL-2 has been found to be low in persistent microbial infections and in cancer.
In summary, IL-2 is a major growth factor for helper T cells, cytotoxic T cells and LAK (lymphokine-activated killer) cells, resulting in: B-cell development; increased lymphokine secretion (IFN-γ, lymphotoxin, IL-4, IL-3, IL-5, GM-CSF); and enhanced MHC class II protein expression. IL-2 and its receptor also occur in the brain, where they promote division and maturation of oligodendrocytes and support the survival of peripheral nervous system neurones in culture.
Because IL-2 should, in principle, be up-regulated in cancer, GUNA's material frames a hyper- or hypo-IL-2 finding in cancer as a signal to challenge for abnormal levels of growth factors — orthophosphotyrosine, insulin-like growth factor, platelet-derived growth factor, epidermal growth factor, fibroblast growth factor, and TGF-α/β — alongside markers relevant to methylation (SAM), B-vitamin physiology (PAG), enzyme-pathway inhibition (key toxins), apoptosis (4-hydroxynonenal), the ATP:ADP ratio, and inflammation (C-reactive protein, serum amyloid protein, NF-κB).
IL-3
Shop Interleukin 03 (IL3)
IL-3 is generated by activated T cells and mast cells. It stimulates eosinophils and B-cell differentiation, inhibits LAK cell activity, and shares biological activities with GM-CSF. It also supports the survival of cholinergic neurones.
IL-4 and IL-5
Shop Interleukin 04 (IL4) · Interleukin 05 (IL5)
IL-4 is derived mainly from Th2 cells (CD4 cells), mast cells and basophils, and is a structural homologue of IL-13. It suppresses production of pro-inflammatory cytokines and of IL-8, and is involved in Th2 subset development and B-lymphocyte production. It switches antibody production toward IgE and IgG, acts as a growth factor for mast cells, and is responsible for CD8 induction. It stimulates VCAM-1 production and enhances MHC class II protein expression (relevant to antigen presentation), and has an anti-inflammatory action in the synovial membrane by inhibiting IL-1, IL-6, IL-8 and TNF-α. Its actions are antagonised by IFN-γ, and vice versa; it is synergistic with IL-3.
IL-5 is derived from Th2 cells (CD4 T helper cells) and activated mast cells, in the same way as IL-4. It stimulates eosinophil growth — relevant to killing helminth parasites — and stimulates B-cell growth and differentiation. It induces IgA and IgM synthesis in mature B-lymphocytes, and enhances T-cell cytotoxicity.
What Follows
The next article in this series continues the reference from IL-6 through IL-12 — the complete range GUNA offers as individual low-dose interleukin remedies — then covers the interferon and tumour necrosis factor families, colony-stimulating factors, transforming and epidermal growth factors, adhesion molecules, and closes with GUNA's own clinical-use table mapping specific cytokines to specific treatment and diagnostic applications.
Featured products
Interleukin 02 (IL2)
Low-dose IL-2, a major growth factor for helper and cytotoxic T cells and a key regulator of immunologic memory.
Anti IL-1
Antagonist-cytokine formula used to brake excess pro-inflammatory IL-1 activity.
Explore the full Guna range — GUNA Method, Cytokines and other GUNA-Method products.
Not sure which remedy is right for you?
Try our Natural Remedy Finder, or contact our team for guidance.
Related reading
- The Complete Interleukin and Cytokine Reference for Practitioners
- The GUNA Method Therapeutic Triangle: PNEI Rebalance, Drainage and Symptom Treatment
Source: GUNA, *Cytokines* clinical reference booklet, pages 1–19.
Tags: Deep Guna Research, Guna Articles, Cytokines